Latest News - Regeneron Pharmaceuticals
Top Corporates Hub
Regeneron Pharmaceuticals
Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z)
27.10.2025 11:30
Conference call today at 8:30 a.m. ETCAMBRIDGE, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that the company has temporarily paused patient dosing and screening for its MAGNITUDE and MAGNITUDE-2 Phase 3 clinical trials of nex-z for patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and polyneuropathy (ATTR-PN), r
OncoNano Medicine Presents First-in-Human Data Demonstrating Safety and Early Signs of Clinical Activity of ONM-501, a Dual-Acting STING Agonist, at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
27.10.2025 11:00
DALLAS, October 27, 2025--OncoNano Medicine, Inc. ("OncoNano") announced encouraging first-in-human results from Part 1 of its Phase 1 ON-5001 trial evaluating ONM-501, a dual-acting STING agonist, as monotherapy and in combination with Libtayo® (cemiplimab), Regeneron’s PD-1 inhibitor, in patients with advanced solid tumors and lymphomas. The findings were shared during a poster presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, M
A Look at Regeneron Pharmaceuticals’s Valuation Following Key European Regulatory Win for Libtayo
27.10.2025 04:17
Regeneron Pharmaceuticals (REGN) just moved a step closer to expanding its cancer therapy portfolio in Europe after the European Medicines Agency’s committee issued a positive opinion for Libtayo as an adjuvant treatment for certain skin cancer patients. See our latest analysis for Regeneron Pharmaceuticals. This regulatory progress adds to a busy stretch for Regeneron, which recently presented at the ESMO Congress and has continued ramping up share repurchases according to major...
Regeneron Earnings: What To Look For From REGN
27.10.2025 03:13
Biotech company Regeneron (NASDAQ:REGN) will be announcing earnings results this Tuesday before market open. Here’s what you need to know.
Earnings Preview: Regeneron (REGN) Q3 Earnings Expected to Decline
21.10.2025 14:00
Regeneron (REGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
REGN Reports Encouraging Data on Gene Therapy for Genetic Hearing Loss (Revised)
16.10.2025 06:54
Regeneron's DB-OTO gene therapy shows hearing gains in nearly all CHORD study participants, with durable and meaningful improvements.
Libtayo® (cemiplimab-rwlc) Approved in the U.S. as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation
08.10.2025 18:31
Approval based on pivotal Phase 3 C-POST trial showing Libtayo significantly reduced the risk of disease recurrence or death by 68% compared to placebo (hazard ratio: 0.32; 95% confidence interval: 0.20-0.51; p<0.0001), the primary endpoint of the trial Libtayo is the current standard of care in advanced CSCC; approval has the potential to change the treatment paradigm for patients in an earlier setting TARRYTOWN, N.Y., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: R
Regeneron Pharmaceuticals Inc. (REGN) Reports Positive Results from Several Late-Stage Trials
02.10.2025 00:10
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 12 Best Widow and Orphan Stocks to Buy According to Analysts. On September 17, 2025, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported positive results from several late-stage trials, highlighting the strength of its pipeline beyond its core ophthalmology franchise. In its Phase 2 COURAGE obesity trial, the combination of […]
Iron Overload Syndrome Market Report 2025-2035, Profiles of Chiesi Group, Novartis, PHARMACOSMOS, Protagonist Therapeutics, Regeneron Pharmaceuticals
01.10.2025 09:43
Iron overload syndrome, including hereditary hemochromatosis, is a disorder marked by excessive iron buildup in the body, primarily due to HFE gene mutations or secondary causes like chronic transfusions. Early diagnosis using serum ferritin and genetic testing is crucial to prevent irreversible damage to organs like the liver and heart. Treatments such as therapeutic phlebotomy, iron chelation, and lifestyle changes effectively manage iron levels. The global market is growing due to improved di
Regeneron’s Evkeeza Receives FDA Approval to Treat HoFH in Children Aged 1 to Less Than 5
01.10.2025 06:16
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the best NASDAQ stocks to buy according to hedge funds. On September 26, Evkeeza (evinacumab-dgnb), an ANGPTL3 antibody developed by Regeneron Pharmaceuticals, received an extended indication approval from the US FDA for the treatment of children from age 1 to less than 5 years old with homozygous familial […]
4D Molecular Therapeutics: This Gene Therapy Company May Soon Surprise Investors
30.09.2025 05:08
4D Molecular Therapeutics (FDMT) offers attractive growth potential with strong cash reserves and promising late-stage gene therapy programs. See more here.
Here’s Why Regeneron Pharmaceuticals (REGN) Fell in Q2
29.09.2025 14:43
Chautauqua Capital Management, a division of Baird Asset Management, is a boutique investment firm that released its second quarter 2025 investor letter for the “Baird Chautauqua International and Global Growth Fund”. A copy of the letter can be downloaded here. Global equity markets experienced a significant shift during the quarter, moving from notable losses to reaching […]
FDA Approves Label Extension of REGN's Cholesterol Drug Evkeeza
29.09.2025 12:28
Regeneron wins FDA approval to extend Evkeeza use in children as young as one with severe familial hypercholesterolemia.
Regeneron’s Evkeeza gains FDA approval for young HoFH patients
29.09.2025 10:02
The decision to broaden the antibody’s indication was based on clinical efficacy and safety data from six children.
1 Healthcare Stock with Exciting Potential and 2 We Ignore
29.09.2025 04:36
Personal health and wellness is one of the many secular tailwinds for healthcare companies. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, limiting growth. This has capped the upside for healthcare stocks lately as the industry’s flat return over the past six months has trailed the S&P 500’s 18.3% gain.
Evkeeza® (evinacumab-dgnb) ANGPTL3 Antibody Approved in the U.S. for Children as Young as 1 Year Old with Ultra-Rare Form of High Cholesterol
26.09.2025 11:00
FDA approval extends the indication of Evkeeza to treat younger patients with homozygous hypercholesterolemia (HoFH) HoFH is an inherited condition characterized by extremely high levels of low-density lipoprotein cholesterol (LDL-C) Initial Evkeeza approval based on placebo-controlled trial showing Evkeeza, when added to standard lipid-lowering therapies, could lower LDL-C by about 50% compared to placebo in this high unmet need population TARRYTOWN, N.Y., Sept. 26, 2025 (GLOBE NEWSWIRE) -- Reg
Regeneron Donates Ebola Treatment for Use in Countries Most at Risk of Outbreaks
19.09.2025 12:00
Inmazeb® (atoltivimab, maftivimab, and odesivimab-ebgn) was the first treatment approved by the U.S. Food and Drug Administration (FDA) for Orthoebolavirus zairense, also known as Zaire ebolavirus Supply is being rushed to Democratic Republic of Congo (DRC) to help with the current outbreak TARRYTOWN, N.Y., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will donate up to 500 doses of Inmazeb® (atoltivimab, maftivimab, and odesivimab-ebgn
Sector Update: Health Care Stocks Edge Higher Late Afternoon
17.09.2025 20:56
Health care stocks were edging up late Wednesday afternoon, with the NYSE Health Care Index up 0.2%
Regeneron Pharmaceuticals (REGN) Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-in-Class Antibody-Blockers of Cat and Birch Allergies
17.09.2025 19:27
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of best affordable biotech stocks to invest in now. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced on September 8 the results evaluating “its first-in-class investigational allergen-blocking antibodies in allergen-challenge Phase 3 trials in adults with moderate-to-severe cat or birch allergies.” The results showed that both trials met their respective primary and […]
Regeneron Says Antibody Combo May Preserve Muscle During Weight Loss
17.09.2025 15:35
Regeneron Pharmaceuticals (REGN) said Wednesday updated Phase 2 trial results suggest that combining